Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis

NCT05374590 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT05374590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05374590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Single-Arm, Open-label, Multicenter Trial to Evaluate Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Lead sponsor
argenx
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
August 18, 2022
Completion date
September 30, 2029
Enrollment
12 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis, gmg